Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2
This article was originally published in The Tan Sheet
Executive Summary
Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year